Loading
A simple clinical score decides between two immunotherapies together or one immunotherapy with a targeted pill.
Intermediate/poor risk: nivolumab-ipilimumab (durable remissions, treatment-free survival) or an IO-TKI doublet (higher response rate, less primary progression). Favourable risk: IO-TKI doublet or TKI alone, since IO-IO shows no OS gain there. Sarcomatoid features favour IO-based therapy regardless of risk.
Shares Sarcomatoid differentiation (RCC), IMDC risk groups (favourable / intermediate / poor), Ipilimumab, Renal cell carcinoma.
Shares IMDC risk groups (favourable / intermediate / poor), Lenvatinib, Renal cell carcinoma, Pembrolizumab.
Shares Axitinib, Lenvatinib, Pembrolizumab, Immune checkpoint inhibitors.
Shares Cabozantinib, Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares IMDC risk groups (favourable / intermediate / poor), Axitinib, Renal cell carcinoma, Pembrolizumab.
Shares Axitinib, Renal cell carcinoma, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Cabozantinib, Lenvatinib, Nivolumab, Small-molecule kinase inhibitors.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.